14 CLINICAL STUDIES CLINICAL STUDIES SECTION 14.1 Cardiovascular Outcomes Trial in Adult Patients with Cardiovascular Disease and Either Obesity or Overweight SPL UNCLASSIFIED SECTION Overview of Clinical Trial Study 1 (NCT03574597) was a multi-national, multi-center, placebo-controlled, double-blind trial to determine the effect of WEGOVY injection relative to placebo on major adverse CV events (MACE) when added to current standard of care, which included management of CV risk factors and individualized healthy lifestyle counseling (including diet and physical activity) in adults with established CV disease and either obesity or overweight
Prepare an injection only when you are ready to give it
NHS Coverage vs Private Prescribing for Obesity Medicines NHS access to weight management medicines requires NICE approval and eligibility criteria
Many users report that appetite suppression becomes truly noticeable around the 5-7.5mg range, with maximum effects kicking in at 10-15mg
California residents only: Consuming this product can expose you to chemicals Including (lead and cadmium), which is [are) known to State of California to cause cancer and birth defects or other reproductive harm
It is not licensed by the MHRA for weight management